MedTrace Logo

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

NCT00272181 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-12-23

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer

Conditions

  • Squamous Cell Carcinoma of the Head and Neck
  • Carcinoma, Squamous Cell
  • Neoplasms, Squamous Cell
  • Head and Neck Neoplasms
  • Mouth Neoplasms
  • Head and Neck Cancer

Interventions

DRUG

Proxinium

Intratumoral administration of Proxinium directly to target tumors.

Sponsors & Collaborators

  • Sesen Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Wendy Cuthbert · Sesen Bio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272181 on ClinicalTrials.gov